| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials
|
André, F.
|
|
|
36 |
1 |
p. 54-64
|
article
|
| 2 |
A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B) ☆
|
Sakai, H.
|
|
|
36 |
1 |
p. 31-42
|
article
|
| 3 |
Artificial intelligence-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma
|
Shimazu, Y.
|
|
|
36 |
1 |
p. 118
|
article
|
| 4 |
Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial
|
Groeneveld, C.S.
|
|
|
36 |
1 |
p. 89-98
|
article
|
| 5 |
Beyond the usual window: persistent nausea with trastuzumab deruxtecan calls for new management strategies
|
Jordan, K.
|
|
|
36 |
1 |
p. 3-5
|
article
|
| 6 |
Breaking the link: IL-6 targeting to uncouple toxicity and efficacy in patients treated with immune checkpoint blockade
|
Roulleaux Dugage, M.
|
|
|
36 |
1 |
p. 6-9
|
article
|
| 7 |
Clinical validation of a tissue-agnostic genome-wide methylome enrichment molecular residual disease assay for head and neck malignancies ☆
|
Liu, G.
|
|
|
36 |
1 |
p. 108-117
|
article
|
| 8 |
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
|
Amaral, T.
|
|
|
36 |
1 |
p. 10-30
|
article
|
| 9 |
Editorial Board
|
|
|
|
36 |
1 |
p. iii
|
article
|
| 10 |
Letter to the Editor regarding ‘A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse’ by JY Blay et al.
|
Hu, Q.
|
|
|
36 |
1 |
p. 119-120
|
article
|
| 11 |
Optimising treatment strategies in metastatic colorectal cancer: insights from CAIRO4
|
Güzel, H.G.
|
|
|
36 |
1 |
p. 121-122
|
article
|
| 12 |
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study ☆
|
Lorusso, D.
|
|
|
36 |
1 |
p. 65-75
|
article
|
| 13 |
Reply to Letter to the Editor “Optimising Treatment Strategies in Metastatic Colorectal Cancer: Insights from CAIRO4” by Güzel et al.
|
de Wilt, J.H.W.
|
|
|
36 |
1 |
p. 122-124
|
article
|
| 14 |
Reply to the Letter to the Editor ‘AI-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma’ by Y. Shimazu
|
Fraunhoffer, N.
|
|
|
36 |
1 |
p. 118-119
|
article
|
| 15 |
Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer ☆
|
Rathkopf, D.E.
|
|
|
36 |
1 |
p. 76-88
|
article
|
| 16 |
Six years duration of adjuvant imatinib improves disease-free survival in GIST with a high risk of relapse
|
Blay, J.-Y.
|
|
|
36 |
1 |
p. 120-121
|
article
|
| 17 |
Subcutaneous versus intravenous nivolumab for renal cell carcinoma ☆
|
Albiges, L.
|
|
|
36 |
1 |
p. 99-107
|
article
|
| 18 |
Table of Contents
|
|
|
|
36 |
1 |
p. i-ii
|
article
|
| 19 |
THANKS TO REFEREES 2024
|
|
|
|
36 |
1 |
p. 1-2
|
article
|
| 20 |
Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study
|
Petit, P.-F.
|
|
|
36 |
1 |
p. 43-53
|
article
|
Journal description